Novartis Pauses Rap-cel Autoimmune CAR-T Trials After IEC-HS Cases
NovartisSigSignificance3.05SenSentiment-4.36EnvEnvironment0.00SocSocial-4.28GovGovernance-2.27
Bristol-Myers SquibbSigSignificance2.31SenSentiment-2.71EnvEnvironment0.00SocSocial-1.68GovGovernance-0.59
Novartis and Bristol Myers Squibb halted multiple autoimmune CAR-T studies after inflammatory side effects in testing. Novartis paused rap-cel trials in lupus, myasthenia gravis and multiple sclerosis, citing three cases of immune effector cell–associated hemophagocytic syndrome, a rare possibly life-threatening reaction. Bristol Myers also paused zola-cel enrollment after transient, reversible inflammation.
Coverage (10)
- Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report (pharmexec.com)
- Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts (biopharmadive.com)
- Three patients die, Novartis halts eight rap-cel clinical trials (idnfinancials.com)
- Novartis, Bristol Myers Squibb pause CAR-T trials for lupus and other autoimmune diseases for safety reviews (lupus.org)
- Novartis halts eight CAR-T cell therapy trials after deaths (emjreviews.com)
- Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events (biospace.com)
- Novartis and Bristol Myers pause CAR-T trials after patient deaths (thepharmaletter.com)
- Novartis, Bristol Myers halt autoimmune CAR-T trials due to adverse events (fiercebiotech.com)
- Novartis, Bristol Myers autoimmune break CAR-T trials due to safety concerns (biopharmadive.com)
- Novartis, Bristol Myers autoimmune break CAR-T trials due to safety concerns (finance.yahoo.com)